Reproductive characteristics in relation to ovarian cancer risk by histologic pathways Ovarian Cancer and Us OVARIAN CANCER and US Ovarian Cancer and Us

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Saturday, January 19, 2013

Reproductive characteristics in relation to ovarian cancer risk by histologic pathways



Reproductive characteristics in relation to ovarian cancer risk by histologic pathways


Author Affiliations
  1. 1Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
  2. 2OB/GYN Epidemiology Center, Department of Obstetrics and Gynecology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
  3. 3Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA
  4. 4Department of Community and Family Medicine, Dartmouth Medical School, Hanover, NH, USA

Abstract

STUDY QUESTION Do reproductive risk factor associations differ across subgroups of invasive epithelial ovarian cancer (EOC) defined by the dualistic model (type I/II) or a histologic pathway-based classification?
SUMMARY ANSWER Associations with parity, history of endometriosis, tubal ligation and hysterectomy were found to differ in the context of the type I/II and the histologic pathways classification of ovarian cancer.
WHAT IS KNOWN ALREADY Shared molecular alterations and candidate precursor lesions suggest that tumor histology and grade may be used to classify ovarian tumors into likely etiologic pathways.
DESIGN This case–control study included 1571 women diagnosed with invasive EOC and 2100 population-based controls that were enrolled from 1992 to 2008. Reproductive risk factors as well as other putative risk factors for ovarian cancer were assessed through in-person interviews.
PARTICIPANTS/MATERIALS, SETTING, METHODS Eligible cases were diagnosed with incident ovarian cancer, were aged 18 and above and resided in eastern Massachusetts or New Hampshire, USA. Controls were identified through random digit dialing, drivers' license and town resident lists and were frequency matched with the cases based on age and study center.
MAIN RESULTS AND THE ROLE OF CHANCE We used polytomous logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for type I/II EOC or using a pathway-based grouping of histologic subtypes. In multivariate analyses, we observed that having a history of endometriosis (OR = 1.92, 95% CI: 1.36–2.71) increased the risk for a type I tumor. Factors that were strongly inversely associated with risk for a type I tumor included parity (≥3 versus 0 children, OR = 0.15, 95% CI: 0.11–0.21), having a previous tubal ligation (OR = 0.40, 95% CI: 0.26–0.60) and more weakly hysterectomy (OR = 0.71, 95% CI: 0.45–1.13). In analyses of histologic pathways, parity (≥3 versus 0 children, OR = 0.13, 95% CI: 0.10–0.18) and having a previous tubal ligation (OR = 0.41, 95% CI: 0.28–0.60) or hysterectomy (OR = 0.54, 95% CI: 0.34–0.86) were inversely associated with risk of endometrioid/clear cell tumors. Having a history of endometriosis strongly increased the risk for endometrioid/clear cell tumors (OR = 2.41, 95% CI: 1.78–3.26). We did not observe significant differences in the risk associations across these tumor classifications for age at menarche, menstrual cycle length or infertility.
LIMITATIONS, REASONS FOR CAUTION A potential limitation of this study is that dividing the cases into subgroups may limit the power of these analyses, particularly for the less common tumor types. Since cases were enrolled after their diagnosis, it is possible that the most aggressive cases were not included in the study.
WIDER IMPLICATIONS OF THE FINDINGS This study provides insights about the role of reproductive factors in relation to risk of pathway-based subgroups of ovarian cancer that with further confirmation may assist with the development of improved strategies for the prevention of these different tumor types. 

STUDY FUNDING/COMPETING INTEREST(S) This research is funded by grants from the National Cancer Institute, the Department of Defense Ovarian Cancer Research Program and the Ovarian Cancer Research Fund. The authors have no competing interests to declare. 

TRIAL REGISTRATION NUMBER Not applicable.

0 comments :

Post a Comment

Your comments?

Note: Only a member of this blog may post a comment.